Dorphan SA Information

DORPHAN S.A. IS A DRUG DISCOVERY AND DEVELOPMENT COMPANY COMMITTED TO THE DEVELOPMENT OF INNOVATIVE THERAPEUTICS FOR THE TREATMENT OF RARE AND DEVASTATING LYSOSOMAL STORAGE DISEASES WITH HIGH UNMET MEDICAL NEED Lysosomal storage diseases are a group of inherited metabolic disorders caused by the deficiency of lysosomal functions, in most cases due to genetic defects in the lysosomal enzymes responsible for the elimination of cellular constituents. In patients affected by lysosomal storage diseases the accumulation over time of a variety of substrates in multiple tissues and organs causes irreversible damages. Our mission is to develop innovative therapies, including pharmacological chaperones, with the objective to rescue lysosomal enzyme function and improve patients’ life.

Website	http://www.dorphan.com
Revenue	$4 million
Employees	2 (0 on RocketReach)
Founded	2011
Address	EPFL Science Park, Lausanne, Vaud 1005, CH
Phone	+41 21 693 85 50
Technologies	JavaScript , PHP , Google Analytics +2 more (view full list)
Industry	Pharmaceutical Manufacturing, Business Services General, Information Technology, Business Services, Medical, Health Care
Keywords	Drug Discovery, Drug Development, Rare Diseases, Innovative Therapeutics, Pharmaceutical Research, Biotechnology, Clinical Trials, Orphan Drugs, Unmet Medical Needs, Genetic Diseases, Enzyme Replacement Therapy, Precision Medicine, Pharmaceutical Development, New Drug Applications, Drug Candidates, Therapeutic Development, Biopharmaceutical, Medical Research
Competitors	Novartis, Pfizer, GSK, AstraZeneca, Moderna Therapeutics, Novavax, CureVac, Zymeworks Inc., INOVIO Pharmaceuticals, Inc., Vaxart, Inc. +38 more (view full list)
SIC	SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies